Lai C.-C.Lee K.-Y.SHU-WEN LINChen Y.-H.HAN-YUEH KUOCHIEN-CHING HUNGPO-REN HSUEH2020-03-272020-03-2720141478-7210https://scholars.lib.ntu.edu.tw/handle/123456789/479864With a broad-spectrum of activity, fluoroquinolones have been widely and successfully used for decades for the treatment of and prophylaxis against various bacterial infections, including community-acquired pneumonia (CAP). However, the use of fluoroquinolones has been compromised by the emergence and spreading of bacterial resistance and the potential for adverse effects. Therefore, there is an unmet need for newer compounds that have a broader spectrum of activity to overcome existing bacterial resistance as well as the potential to minimize the risk of adverse effects. Nemonoxacin (TG-873870), a newly developed quinolone, has demonstrated broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens, including drug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus. Results from Phases I and II studies of treatment of CAP are encouraging. This article reviews the updated data on nemonoxacin, including the bacterial susceptibility, the pharmacologic characteristics, and toxicities, and clinical trials using nemonoxacin for treatment of CAP. ? 2014 Informa UK, Ltd.[SDGs]SDG3alanine aminotransferase; amylase; aspartate aminotransferase; bilirubin; creatine kinase; levofloxacin; nemonoxacin; placebo; triacylglycerol lipase; antiinfective agent; nemonoxacin; quinolone derivative; abdominal pain; anemia; antibacterial activity; antibiotic sensitivity; article; bilirubin blood level; community acquired pneumonia; diarrhea; dizziness; dose response; drug absorption; drug dose comparison; drug efficacy; drug metabolism; drug safety; drug structure; epilepsy; headache; human; hyperglycemia; intracardiac thrombosis; leukopenia; lung abscess; maximum plasma concentration; nausea; neutropenia; nonhuman; pharmacodynamics; phase 2 clinical trial (topic); phase 3 clinical trial (topic); pneumonia; pruritus; QT prolongation; rash; sepsis; thrombocytopenia; time to maximum plasma concentration; treatment outcome; tuberculosis; unspecified side effect; valvular heart disease; antibiotic resistance; chemistry; clinical trial (topic); Community-Acquired Infections; microbial sensitivity test; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Quinolonesjournal article10.1586/14787210.2014.894881245798132-s2.0-84896385409